



PRELIMINARY PROGRAMME (as of January, 2017)

THURSDAY APRIL 6th 2017

- 08.45 - 09.00** **ILAE address and opening of the conference**
E. Perucca (Italy), E. Trinka (Austria), S. Shorvon (UK)
- 09.00 – 10.40** **The nature of status epilepticus: experimental aspects I**
D. Kullman (UK), H. Cock (UK)
- 09.00 - 09.20** **Mitochondrial diseases and status epilepticus**
S. Rahman (UK)
- 09.20 - 09.40** Discussion
- 09.40 - 10.00** **Circuit mechanisms in status epilepticus**
J. Kapur (USA)
- 10.00 - 10.20** Discussion
- 10.20 - 10.40** **Receptor trafficking**
J. Kittler (UK)
- 10.40 - 11.00** Discussion
- 11.00 - 11.30** Break
- 11.30 – 13.00** **The nature of status epilepticus: experimental aspects II**
M. Rogawski (USA), M. Walker (UK)
- 11.30 - 11.50** **Epigenetic changes in status epilepticus**
D. Henshall (Ireland)
- 11.50 - 12.10** Discussion
- 12.10 - 12.40** **Genetics of Experimental Epilepsy**
M. Simonato (Italy)
- 12.40 – 13.00** Discussion
- 13.00 - 14.00** **Lunch and posters**
- Satellite symposium 1**



14.00 – 16.00 The nature of status epilepticus: clinical aspects I

R. Kälviäinen (Finland), G. Bauer (Austria)

14.00 - 14.20 Next generation sequencing in the diagnosis of encephalitis

W. I. Lipkin (USA)

14.20 - 14.40 Discussion

14.40 - 15.00 Boundary syndromes

S. Shorvon (UK)

15.00 - 15.20 Discussion

15.20 - 15.40 Status epilepticus due to poisons in warfare

A. M. Marini (USA)

15.40 - 16.00 Discussion

16.00 - 16.30 Break

16.30 – 17.50 The nature of status epilepticus: clinical aspects II

S. Basic (Croatia), A. Neligan (UK)

16.30 - 16.50 Neuroimaging of status epilepticus

S. Meletti (Italy)

16.50 - 17.10 Discussion

17.10 - 17.30 Treatment gap in developing countries

B. Lee (South Korea)

17.30 - 17.50 Discussion

19.00 Reception



FRIDAY APRIL 7th 2017

08:30 – 10:30	Status epilepticus in the Intensive Care Unit I N. Abend (USA), P. Kaplan (USA)
08.30 - 08.50	NCSE – types and EEG E. Trinka (Austria)
08.50 - 09.10	Discussion
09.10 - 09.30	Prognostic scales in status epilepticus W. Jiang (China)
09.30 – 09.50	Discussion
09.50- 10.10	Anaesthetic treatment of status epilepticus S. Hocker (USA)
10.10 - 10.30	Discussion
10.30 - 11.00	Break
11.00 – 13.00	Status epilepticus in the Intensive Care Unit and the weaning of anaesthetics C. Baumgartner (Austria), T. Bleck (USA)
11.00-11.20	Guidelines for the weaning of anaesthetics H. Colquhoun (USA)
11.20-11.40	Experience with weaning and cycling of anaesthetics A. Cole (US)
11.40-12.00	Discussion on the topic of weaning anaesthetics
12.00-12.20	Long term consequences of intensive care treatments - a critical assessment T. Loddenkemper (USA)



12.20-12.40	Status epilepticus in the elderly I. Leppik (USA)
12.40-13.00	Discussion
13.00-14.00	Lunch and posters
14.00-15.00	Some regulatory aspects of Status Epilepticus
14.00-14.40	Debate and panel discussion: 'Is Status Epilepticus an entity ?' S. Shorvon (UK) Panel: tbc
14.40 – 15.00	What evidence do we need to license a drug for status epilepticus? E. Trinka (Austria)
15.00 - 15.30	Break
15.30 – 17.10	Audits and registries F. Minicucci (Italy), A. Strzelczyk (Germany)
15.30 - 15.50	The global audit of refractory status epilepticus S. Hocker (USA) and M. Ferlisi (Italy)
15.50 - 16.00	Discussion
16.00 - 16.20	SENSE registry for status epilepticus C. Kellinghaus (Germany)
16.20 - 16.30	Discussion
16.30 - 16.50	Lessons learned from the FEBSTAT study S. Shinnar (USA)
16.50 - 17.00	Discussion
17.00 - 17.30	Break
17.30 - 18.30	Free communications



SATURDAY APRIL 8th 2017

08.30 – 10.00 **Future perspectives, novel therapy and innovation I**

A. Rossetti (Switzerland), N.N.

08.30 - 08.50 **Propofol Hemisuccinate**

M. Rogawski (USA)

08.50 - 09.00 Discussion

09.00 - 09.20 **Valnoctamide and SPD for acute seizures and status epilepticus**

M. Bialer (Israel)

09.20 - 09.30 Discussion

09.30 - 09.50 **Brivaracetam**

E. Trinko (Austria)

09.50 - 10.00 Discussion

10.00 - 10.30 Break

10.30 – 14.00 **Future perspectives, novel therapy and innovation II**

N. Bharucha (India), S. Ruegg (Switzerland)

10.30 – 10.50 **Perampanel – an oral AMPA antagonist**

A. Rohrer (Austria)

10.50 – 11.00 Discussion

11.00 - 11.20 **Place of neurosteroids in the treatment of status epilepticus**

A. Rossetti (Switzerland)

11.20 - 11.30 Discussion

11.30 - 11.50 **Ketamine**

J. Höfler (Austria)

11.50 - 12.00 Discussion

12.00 - 12.20 **New modes of administration**

J. Cloyd (USA)

12.20 - 12.30 Discussion



12.30 - 12.50	Canine status epilepticus – implications for humans W. Löscher (Austria)
12.50 – 13.00	Discussion
13.00 - 13.20	Decanoic acid M. Walker (UK)
13.20 - 13.30	Discussion
13.30 - 13.50	Update ESET Trial J. Kapur (USA)
13.50 – 14.00	Discussion
14.00 – 14.15	Concluding remarks S. Shorvon (UK), E.Trinka (Austria)
	Farewell lunch